Skip to content

DiaSurg Study - A prospective study for the clinical evaluation of the effect of a gastric bypass on insulin dependent type 2 diabetes mellitus in non-severely obese patients

DiaSurg Study - A prospective study for the clinical evaluation of the effect of a gastric bypass on insulin dependent type 2 diabetes mellitus in non-severely obese patients - DiaSurg-Study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
DRKS
Registry ID
DRKS00004605
Enrollment
20
Registered
2013-01-02
Start date
2010-10-16
Completion date
Unknown
Last updated
2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

E11

Interventions

Group 1: laparoscopic Roux-en-Y gastric bypass - gastrojejunostomy and jejunojejunostomy

Sponsors

Universitätsklinikum Heidelberg
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: An insulin-dependent T2DM for at least 3 months and daily requirement of > 10IE insulin, BMI from 25 to 35 kg/m², HbA1c > 7% and a residual endocrine pancreatic function which was assessed by stimulated C-peptide laboratory tests with a minimum of 1.5 ng/ml.

Exclusion criteria

Exclusion criteria: Patients were excluded from this study if they could not satisfy the inclusion criteria. Moreover, the suspicion of a diabetes mellitus type 1 or autoimmune diabetes prevented study participation. Other exclusion criteria were clinical cardiac disease in stages III and IV according to the classification of the New York Heart Association, and an unstable coronary artery disease, renal failure with a glomerular filtration rate <45ml/min, chronic obstructive pulmonary disease requiring therapy, immunosuppression / glucocorticoids, previous extensive abdominal surgery, pregnancy, addictive disorders, an active malignant tumor within the last 10 years, pituitary disease (Addison's disease), and a lack of their own capacity to consent.

Design outcomes

Primary

MeasureTime frame
Diabetes remission after RYGB. Determination by blood samples (fasting glucose, HbA1c) and medical treatment

Secondary

MeasureTime frame
The reduction of comorbidities such as hypertension and dyslipidemia is determined by the measurement of blood pressure, medication history and the level of the blood lipids. The reduction of comorbidities such as neuropathy is evaluated through questionnaires (neuropathy symptom score, neuropathy deficit score) and the course of nephropathy is determined by blood tests (creatinine, urea, glomerular filtration rate). In addition a cost-benefit analysis is conducted.

Countries

Germany

Contacts

Public ContactBeat Müller

Universitätsklinikum Heidelberg Sektion Minimal Invasive CHirurgie

adipositaszentrum@med.uni-heidelberg.de06221- 566883

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Mar 15, 2026